Frequently Asked Questions

It is useful when the diagnosis is serious, staging is unclear, treatment options differ, or surgery, chemotherapy, targeted therapy, immunotherapy, or radiation is being considered. It reduces uncertainty rather than replacing the primary doctor.

Pathology, imaging, staging tests, treatment history, medications, genomic results, and the key question should be prepared. Better records make it easier to judge whether new tests or treatment changes are needed.

No. Screening should be based on age, family history, medical history, risk factors, and the screening goal. Over-screening can create false positives, anxiety, and unnecessary follow-up.

Pressure, sleep debt, travel, irregular exercise, business meals, and metabolic dysfunction can silently accumulate risk. The focus is early review of blood pressure, lipids, glucose, inflammation, coronary status, and lifestyle rhythm.

Not always. It depends on symptoms, stenosis severity, ischemia evidence, overall risk, and physician assessment. Many cases first require risk stratification, medication, and lifestyle management.

If memory affects work, financial judgment, navigation, language, or family members notice clear change, it should not be dismissed as aging. Sleep, mood, medications, metabolism, vascular, and neurodegenerative risks should be assessed.

It may help when diagnosis is uncertain, medication response is complex, or DBS, rehabilitation, or research options are being considered. Disease course, medication response, imaging, and scales matter.

Not always. Glucose, insulin resistance, weight, fatty liver, family history, and cardiovascular risk matter. Some start with nutrition, exercise, sleep, and weight management; others need medication review.

Self-directed supplements are not enough. Symptoms, underlying disease, breast and gynecologic risk, bone density, metabolism, and medications should be reviewed before medical intervention.

Physician qualification, clinic compliance, indications, contraindications, risk disclosure, and aftercare come first. Price is a later comparison point, not a safety standard.

Regenerative aesthetics may involve cells, exosomes, PRP, or tissue-repair concepts, with more complex evidence and regulatory boundaries. Claims of permanent or dramatic age reversal should be treated cautiously.

No. Suitability depends on indications, health status, risk factors, institution quality, and evidence level. For healthy clients, baseline assessment, lifestyle, and risk management often come first.

It should start with goals: which risks to reduce, which functions to improve, and which trends to manage. Testing creates baselines and reviews; it should not be done for its own sake.

A standard checkup looks for current disease. Longevity medicine focuses on future risk, functional decline, biological age, sleep, metabolism, inflammation, and healthspan.

It is not a marketing score for looking younger. It helps establish a baseline and track whether metabolism, inflammation, recovery, and aging speed are drifting.

Executive risk often comes from pressure, sleep debt, travel, irregular meals, and decision load. Screening should address cardiovascular, metabolic, sleep, cancer, and cognitive risk.

Both may matter. It is useful to assess sleep apnea, metabolic issues, medication effects, stress rhythm, and cardiovascular risk before choosing an intervention.

Regenerative medicine involves institution credentials, physician assessment, program documentation, cell source, processing standards, and adverse-event management.

Clients with unclear history, active major disease, complex medication, vague goals, or incomplete records should first undergo record review and physician assessment.

No. Review institution credentials, physician background, filings, cell source, processing workflow, risk disclosure, follow-up, and over-promising.

No. Exosomes relate to extracellular vesicles and cell signaling, while stem cells involve cells themselves. Evidence, regulation, and risk boundaries differ.

Japan offers a stable medical system, detailed screening culture, strong privacy, dense university and specialty resources, and a relatively clear regenerative medicine framework.

When a diagnosis is serious, treatment is high-risk, information conflicts, referral is cross-border, or the family cannot judge the next step.

No. Screening should reflect age, family history, medical history, lifestyle, and risk goals. Over-screening can create false positives and unnecessary decisions.

It should include annual checkups, imaging, medications, genomic or biological-age data, major opinions, referrals, follow-up plans, and family risk alignment.